Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$1.58 -6.0%	$2.10	$1.55 ▼ $17.31	$38.49M	N/A	171,643 shs	420,073 shs
CLNN Clene	$4.28 -2.1%	$3.24	$2.28 ▼ $8.00	$38.45M	0.49	89,824 shs	64,162 shs
CUBT Curative Biotechnology	$0.01 +11.1%	$0.01	$0.00 ▼ $0.03	$10.15M	0.36	82,451 shs	677,736 shs
SEOVF Sernova Biotherapeutics	$0.12	$0.14	$0.10 ▼ $0.29	$39.02M	1.08	27,181 shs	1,004 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	0.00%	-20.20%	-20.20%	-63.00%	+157,999,900.00%
CLNN Clene	0.00%	+4.39%	+74.69%	+3.38%	-43.70%
CUBT Curative Biotechnology	0.00%	+2.04%	-32.89%	-35.06%	-42.86%
SEOVF Sernova Biotherapeutics	-0.04%	-5.60%	-24.84%	-2.02%	-47.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTV Artiva Biotherapeutics	2.7847 of 5 stars	3.5	0.0	0.0	0.0	2.6	1.7	1.3
CLNN Clene	2.4623 of 5 stars	3.6	3.0	0.0	0.0	0.6	2.5	0.6
CUBT Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	3.00	Buy	$17.80	1,026.58% Upside
CLNN Clene	3.17	Buy	$40.00	834.58% Upside
CUBT Curative Biotechnology	0.00	N/A	N/A	N/A
SEOVF Sernova Biotherapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CUBT, SEOVF, ARTV, and CLNN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$12.00
5/15/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $18.00
5/8/2025	CLNN Clene	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $33.00
5/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/23/2025	CLNN Clene	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
4/8/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/8/2025	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/26/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/25/2025	ARTV Artiva Biotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$23.00 ➝ $20.00
3/25/2025	ARTV Artiva Biotherapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00 ➝ $18.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	$250K	153.96	N/A	N/A	$7.68 per share	0.21
CLNN Clene	$340K	113.04	N/A	N/A	($1.06) per share	-4.04
CUBT Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	($0.03) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$65.37M	N/A	0.00	N/A	N/A	N/A	-75.95%	-39.51%	6/23/2025 (Estimated)
CLNN Clene	-$39.40M	-$4.04	N/A	N/A	N/A	-8,306.00%	-1,106.30%	-105.11%	8/6/2025 (Estimated)
CUBT Curative Biotechnology	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SEOVF Sernova Biotherapeutics	-$23.65M	-$0.04	N/A	∞	N/A	N/A	N/A	-358.68%	N/A

Latest CUBT, SEOVF, ARTV, and CLNN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/13/2025	Q2 2025	SEOVF Sernova Biotherapeutics	N/A	-$0.01	N/A	-$0.01	N/A	N/A
5/8/2025	Q1 2025	ARTV Artiva Biotherapeutics	-$0.68	-$0.83	-$0.15	-$0.83	N/A	N/A
5/7/2025	Q1 2025	CLNN Clene	-$1.10	-$0.50	+$0.60	-$0.09	$0.07 million	$0.08 million
3/24/2025	Q4 2024	CLNN Clene	-$1.21	-$1.67	-$0.46	-$1.67	$0.13 million	$0.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CLNN Clene	N/A	N/A	N/A	N/A	N/A
CUBT Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	13.93	13.93
CLNN Clene	N/A	1.36	1.36
CUBT Curative Biotechnology	N/A	N/A	N/A
SEOVF Sernova Biotherapeutics	N/A	0.10	0.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
CLNN Clene	23.28%
CUBT Curative Biotechnology	N/A
SEOVF Sernova Biotherapeutics	N/A

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	21.40%
CLNN Clene	35.30%
CUBT Curative Biotechnology	N/A
SEOVF Sernova Biotherapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	24.36 million	19.15 million	N/A
CLNN Clene	100	8.98 million	5.81 million	Optionable
CUBT Curative Biotechnology	N/A	1.02 billion	N/A	Not Optionable
SEOVF Sernova Biotherapeutics	N/A	328.48 million	N/A	Not Optionable

CUBT, SEOVF, ARTV, and CLNN Headlines

Recent News About These Companies

Sernova Biotherapeutics Taps CEO to Be Interim Chair

June 2, 2025 | marketwatch.com

Sernova Appoints Jonathan Rigby as Interim Chair

June 2, 2025 | globenewswire.com

Chair of Sernova Biotherapeutics Resigns

May 26, 2025 | globenewswire.com

Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes

May 22, 2025 | globenewswire.com

Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes

May 14, 2025 | globenewswire.com

Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans

April 17, 2025 | globenewswire.com

Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med

April 15, 2025 | globenewswire.com

Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes

April 1, 2025 | globenewswire.com

Sernova names Pericles Calias as CDO and head of R&D

March 11, 2025 | thepharmaletter.com

Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D

March 10, 2025 | globenewswire.com

Sernova Biotherapeutics Secures $1 Million Convertible Debt Financing

March 5, 2025 | globenewswire.com

Sernova Biotherapeutics Receives FDA Clearance for IND Application for its Cell Pouch Bio-hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism

March 3, 2025 | globenewswire.com

Sernova Biotherapeutics Submits IND Application for its Cell Pouch Bio-Hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism

February 3, 2025 | globenewswire.com

Sernova Corp. Shareholders Approve Key Resolutions at Annual Meeting

January 14, 2025 | tipranks.com

Sernova Advances Diabetes Cure with Strategic Initiatives

January 14, 2025 | tipranks.com

Sernova Financial joins FIA Tech’s Databank Network

January 13, 2025 | finextra.com

Sernova Announces Voting Results from its Annual and Special General Meeting of Shareholders

January 13, 2025 | finance.yahoo.com

Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025

December 20, 2024 | globenewswire.com

FDA fast tracks type 1 diabetes cell therapy from Vertex

November 9, 2024 | pharmaphorum.com

Sernova to Present at the 2024 Cell & Gene Meeting on the Mesa

October 3, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUBT, SEOVF, ARTV, and CLNN Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$1.58 -0.10 (-5.95%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.63 +0.05 (+3.16%)

As of 06/20/2025 07:43 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Clene NASDAQ:CLNN

$4.28 -0.09 (-2.06%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.28 0.00 (0.00%)

As of 06/20/2025 05:55 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Curative Biotechnology OTCMKTS:CUBT

$0.01 +0.00 (+11.11%)

As of 06/20/2025 03:46 PM Eastern

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.

Sernova Biotherapeutics OTCMKTS:SEOVF

$0.12 0.00 (0.00%)

As of 06/20/2025

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time